Qu et al. demonstrated that a score including several cfDNA mutations (TP53, TERT, CTNNB1 and AXIN1, and HBV integrations), in combination with protein biomarkers (AFP and DCP), age and gender efficiently identified early-stage HCC in a high-risk HBsAg-seropositive population [60]. This evidence concerns the gene ACE and hepatocellular carcinoma.